An advisory panel to the U.S. Food and Drug Administration (FDA) recommended that the opioid reversal nasal spray Narcan should become an over-the-counter drug.
Narcan, or naxolone, is the most commonly sold medication to deal with opioid overdoses. Emergent BioSolutions Inc. submitted an application to the FDA late last year to allow it to sell generic naloxone hydrochloride without a prescription.
The FDA panel’s vote Wednesday is a recommendation. The drug regulator will have to make the final call on approving Narcan for over-the-counter use in the coming days or weeks.
An FDA official said that Narcan appears to have minimal risks. Other speakers, meanwhile, noted that opioid drug overdoses have skyrocketed in the United States in recent years, namely due to the synthetic drug fentanyl.
“The safety of Narcan nasal spray has been very well established. There appear to be very minimal risks, if any, in terms of unintended effects or unintended serious effects that are worse than the alternative of not treating a patient,” said Maria Coyle, chairwoman of the FDA’s Nonprescription Drugs Advisory Committee. “We, as a committee, appear to be in support of the safety profile.”
If it becomes a nonprescription produce, Narcan “may be sold at many venues besides pharmacies, such as vending machines, convenience stores, supermarkets, [and] big box stores,” the report said.
“Over seven years of having marketed this product, we know that this product is very easy to use. It is being used by a variety of community groups, including lay individuals. It is a single four milligram dose that is safe and effective,” Manish Vyas of Emergent BioSolutions told the panel.

Their paper examined data from 2006 to 2015 and found that after laws made naloxone easier to access, opioid-related emergency room visits and crimes increased. They found that opioid-related deaths increased by 14 percent in Midwest states.
But when their study was published, some researchers said it had critical flaws.